MarketPulse

setrusumab

46 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Investor Lawsuits Filed Against Ultragenyx and Mereo Over Failed Clinical Trials

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.
MREORAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Setrusumab Trial Disclosures

Mereo BioPharma faces securities lawsuit for allegedly making false statements about setrusumab trial results, causing artificially inflated stock prices and investor losses.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Ultragenyx Investors Face April Deadline in Securities Fraud Class Action

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.
RAREsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Ultragenyx Over Setrusumab Trial Disclosures

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Investors Face April Deadline in Securities Lawsuit Over Failed Trials

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Ultragenyx Investors Face April Deadline in Securities Litigation Over Setrusumab Claims

Ultragenyx faces securities lawsuit alleging misleading claims about setrusumab's efficacy. Investors must act by April 6, 2026 deadline to join class action.
RAREsecurities fraudclass action lawsuit